

REMARKS**Interview Summary**

Applicants' Attorney, Steven G. Davis, and Applicants' Agent, Booyong S. Lim, would like to thank Examiner James D. Anderson for the interview held on January 29, 2008 for the above-identified application.

During the interview of January 29, 2008, as summarized in the Interview Summary PTOL-413 of January 29, 2008, an agreement was reached, and the claim amendments presented herein are essentially the same as those agreed during the interview.

Amendments to the Specification

The specification has been amended to replace all occurrences of "taxol" with "TAXOL" or "paclitaxel"; and to replace all occurrences of "taxotere" with "docetaxel" or "TAXOTERE". Support for these amendments can be found, for example, at page 33, lines 5-7.

No new matter has been added.

Amendments to the Claims

Claims 1-7, 15, 18-24, 32 and 36 have been canceled. Claims 8 and 25 have been rewritten as independent claims and have been further amended to recite that "R¹ and R² are each a substituted or unsubstituted phenyl group," as suggested by the Examiner during the interview of January 29, 2008. Support for these amendments can be found, for example, at page 17, lines 16-18, which states that phenyl is one example of an aromatic group. Claim 11, dependent from Claim 10, has been amended to delete the recitation "R¹ and R² are each a substituted or unsubstituted phenyl group," which is incorporated into currently amended Claim 10. Claims 12 and 29 have been amended to more clearly define Applicants' claimed invention.

Claims 13 and 30 have been rewritten as independent claims and have been further amended to recite that "R³ and R⁴ are both substituted or unsubstituted alkyl groups." Support for these amendments can be found, for example, at page 13, lines 8-12. Claim 16 has been amended to depend from Claim 13. Claim 28, dependent from Claim 25, has been amended to delete the recitation "R¹ and R² are each a substituted or unsubstituted phenyl group," which is

incorporated into currently amended Claim 25. Claim 33 has been amended to depend from Claim 30.

Claims 34 and 35 have been rewritten as independent claims. Claims 34 and 35 have been further amended to add the recitation "or a pharmaceutically acceptable salt thereof," and to delete the second structural formula, which is incorporated into the new Claims 43 and 44. Claims 37-39 have been amended to correct claim dependencies. Claim 38 has been further amended to delete breast carcinoma.

New Claims 40-50 have been added. Support for new Claims 40-42, 44-46 and 48-50 can be found, for example, at page 20, line 25 through page 22, line 13. Support for new Claims 43 and 47 can be found, for example, at page 3, lines 7-8; page 4, lines 13-19, original Claim 34 and Example 12.

No new matter has been added.

Claim Rejection under 35 U.S.C. § 112, 1st Paragraph

Claims 1-35 and 37-38 were rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement.

As agreed with the Examiner during the interview of January 29, 2008, the subject matter of currently-presented claims, fully supported by the present specification, meets the enablement requirement of 35 U.S.C. § 112, first paragraph. Accordingly, Applicants respectfully request that the Examiner reconsider and withdraw the rejection under 35 U.S.C. § 112, first paragraph.

Supplemental Information Disclosure Statement

A Supplemental Information Disclosure Statement (IDS) is being filed concurrently herewith. Although Applicants believe that the most relevant references have already been cited, in an abundance of caution, Applicants are now citing additional references discussed in greater detail below. Entry of the Supplemental IDS is respectfully requested.

References AF2-AI2 are issued patents (U.S. Patent Nos 6,800,660, 6,762,204, 6,924,312 and 7,037,940) from the same patent family as US2003/0119914 and US 2003/0045518 (Attorney docket no. 3211.1000 family) claiming bis(thio-hydrazide amide) compounds and their method of use. US2003/0119914 and US 2003/0045518 were cited as References AA and AB,


respectively, during the prosecution of the instant application in an Information Disclosure Statement filed June 29, 2004. AA3 and AB3 are two pending applications (recently allowed) in the same patent family (Attorney docket no. 3211.1000 family). References AL2, AS2-AZ2 are references cited in these two pending applications. References AJ2, AK2, AC3-AI3, AM2-AL3 and non-published pending applications submitted herewith are issued patents and patent applications disclosing the same or similar bis(thio-hydrazide amide) compounds as in 3211.1000 family.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Xin Zhang
Registration No. L0410
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date: 3/14/08